A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Phase of Trial: Phase I/II
Latest Information Update: 10 Oct 2017
At a glance
- Drugs Olaratumab (Primary) ; Docetaxel; Gemcitabine
- Indications Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms ANNOUNCE 2
- Sponsors Eli Lilly
- 25 Aug 2017 Planned End Date changed from 1 Aug 2020 to 1 Jul 2020.
- 25 Aug 2017 Planned primary completion date changed from 1 Mar 2020 to 1 Aug 2019.
- 10 Aug 2017 Planned number of patients changed from 215 to 310.